Assay-kits

SensoLyte® Anti-MOG(35-55) IgG Quantitative ELISA Kit (mouse/rat) Colorimetric - 1 kit

443,00
Check your price
  • Cat.Number : AS-54465
  • Availability :
    In stock
  • Shipping conditions : Ice delivery fees must be applied

Select specification

Quantity

MOG peptide fragment (35-55) [Cat# AS-60130] induces autoantibody production and relapsing-remitting neurological disease causing extensive plaque-like demyelination. Autoantibody response to MOG (35-55) is present in multiple sclerosis (MS) patients and MOG (35-55)-induced experimental autoimmune encephalomyelitis (EAE) mice.
The SensoLyte® Anti-MOG (35-55) IgG Quantitative ELISA Kit (mouse/rat) provides a convenient, quantitative assay for detecting anti-MOG (35-55) IgG. This colorimetric assay, useful for determining the amount of anti-MOG (35-55) IgG present, can help provide information on the role anti-MOG (35-55) IgG plays in the development of EAE, an in vivo animal model for MS pathogenesis. The assays are performed in a convenient 96-well (strips format).

Specifications

Packaging
Kits components
  • Component A: MOG (35-55) coated and BSA blocked 8-well strips: 12 strips Component B: Mouse anti-MOG (35-55) IgG standard: 100 µl (20 µg/ml) Component C: 1X Sample Dilution Buffer: 30 ml Component D: 10X Wash Buffer: 50 ml Component E: TMB color substrate solution: 10 ml Component F: Stop Solution: 10 ml Component G: Secondary antibody, Goat anti-Mouse IgG-HRP: 30 µl Component H: Secondary antibody, Goat anti-Rat IgG-HRP: 30 µl Component J: Rat anti-MOG (35-55) IgG standard: 100 µl (20 µ
Chemistry
UniProt number
  • Q61885, Q63345
Storage & stability
Storage Conditions
  • Store all kit components at 2-8°C for up to 6 months.
Activity
Application
Biomarker Target
Detection Method
Detection Limit
  • 1 ng/ml
Research Area
Sub-category Research Area
Usage
  • Research use

You may also be interested in the following product(s)

Citations

Cerebrospinal fluid dendritic cells infiltrate the brain parenchyma and target the cervical lymph nodes under neuroinflammatory conditions

PLoS ONE . 2008 Oct 02 ; 3 e3321 | DOI : 10.1371/journal.pone.0003321

  • E. Hatterer
  • et al